Cost Analysis of Antihypertensive Agents in Rural Population: A Prospective Study
Objective: To calculate the direct medical and non-medical cost, indirect non-medical cost of prescription involved in the treatment of hypertension in rural inpatients at tertiary care teaching hospital.
Methods: A cross sectional, prospective and patient based cost of illness study was conducted in tertiary care hospital, Chidambaram for 12 mo and 267 new prescriptions was selected for the analysis. The data collected from the prescription included patientâ€™s socio-demographics, hypertension stage, drug therapy consumption, anti-hypertensive category and cost of each drug. Drug procurement costs were calculated, by using the TNG medical supply list of the most commonly prescribed drugs, for each drug on a daily and annual basis.
Results: Mean patient age were 60.6Â±10.5 y. 41.9% patients were having prevalence of hypertension at the age of above 60 y, 52.8% were males and 47.2% were females. The mean (systolic/diastolic) blood pressure was 141.8 mmHg (Â±15.2). Average annual direct medical costs were found to be â‚¹1,408,082.4, average annual direct non-medical cost was â‚¹9171.4 and the average annual indirect non-medical costs incurred by productivity loss were â‚¹10789.2.
Conclusions: Direct and indirect non-medical costs have incurred high when compared with the other costs. The annual average total direct (medical and non-medical) costs per patient and total cost of illness were â‚¹1,417,253.8 and â‚¹27,993,470.0 respectively.
Keywords: Cost-of-illness, Hypertension, Therapy consumption, Direct medical and non-medical cost, Indirect non-medical cost and morbidity cost
2. Mahmood SE, Anurag Srivastava, Shrotriya VP, Iram S, Payal M. Prevalence and epidemiological correlates of hypertension among labour population. Nat J Comm Med 2011;2:43-8.
3. Sunday OA, Nse OE, Aniefiok JU. Evaluation of prescribing pattern and quality of pharmaceutical care for hypertensive patients in Southern Nigeria. Indian J Novel Drug Delivery 2011;3:24-8.
4. Muna AS, Mohamed AA Hassali, Mohamed Izham MI. Evaluation of direct medical cost in treating hypertension in a malaysian public University. Asian J Pharm Clin Res 2010;3:170-3.
5. Andrew HB, Adrian RL. Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven? Pharmacoeconomics 2006;24:1079-86.
6. Lisa Sanchez Trask. Pharmacoeconomics: Principles, Methods, and applications. The McGraw-Hill Companies: Foundation issues section; 2011.
7. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment Oslo; 2013.
8. Pritchard C, Sculpher M. Productivity Costs: Principles and Practice in Economic Evaluation: Office of Health Economic London; 2000.
9. Sun Q, Liu X, Meng Q, Tang S, Yu B, Tolhurst R. Evaluating the financial protection of patients with chronic disease by health insurance in rural China. Int J Equity Health 2009;8:42-6.
10. Patricia M Kearney, Megan Whelton, Kristi Reynolds, Paul K Whelton, Jiang He. Worldwide prevalence of hypertension: a systematic review. J Hyper 2004;22:11â€“9.
11. Marta Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009;27:963â€“75.
12. Cai Le, Shu Zhankun, Dong Jun, Zhao Keying. The economic burden of hypertension in rural south-west China. Trop Med Int Health 2012;17:1544â€“51.
13. Giwa Abdulganiyu, Tayo Fola. What is the cost of illness of Type II diabetes mellitus in a developing economy? Int J Pharm Pharm Sci 2014;6:927-31.